EGFR and lung cancer: Interestingly, the risk of BM seems to be 2-3 times higher in EGFR-mutated lung cancers compared to wildtype, and one third of these patients will develop intracranial progression sometime during their disease course, underscoring high neurotropism of these EGFR-mutant tumors (22–24).